Single agent chemotherapy with Erlotinib

3 trials

Sponsors

Okayama Lung Cancer Study Group, Fujita Health Universty Hospital Division of Respirology and Allergology, Yamaguchi Thoracic Oncology Group(YTOG)

Conditions

Non-small cell lung cancernon-small cell lung cancerrelapsed non-small-cell lung cancer

Phase 2

Phase II study of erlotinib monotherapy for relapsed patients with non-small-cell lung cancer who do not possess any active EGFR gene mutations

Active, not recruitingJPRN-UMIN000001509

Okayama Lung Cancer Study Grouprelapsed non-small-cell lung cancer

Start: 2008-01-01Target: 30Updated: 2026-06-29

A Phase II Study for the efficacy and safety of Erlotinib for Patients previously treated Non-small cell Lung Cancer Patients with EGFR Mutations

RecruitingJPRN-UMIN000003215

Fujita Health Universty Hospital Division of Respirology and AllergologyNon-small cell lung cancer

Start: 2009-11-01Target: 28Updated: 2026-06-29

Phase II study to investigate efficacy and safety of erlotinib in patients with advanced and recurrent NSCLC with poor performance status

RecruitingJPRN-UMIN000003540

Yamaguchi Thoracic Oncology Group(YTOG)non-small cell lung cancer

Start: 2010-03-01Target: 20Updated: 2026-06-29